[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567541":3},{"organization":4,"outcomesModule":7,"designInfo":19,"detailedDescription":18,"studyPopulation":18,"armGroups":26,"interventions":34,"overallOfficials":44,"centralContacts":48,"locations":57,"responsibleParty":77,"collaborators":80,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":91,"sex":92,"minAge":93,"maxAge":18,"enrollmentInfo":94,"targetDuration":18,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":60,"whyStopped":18,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"University of Alabama at Birmingham","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":18},[9],{"measure":10,"description":11,"timeFrame":12},"Conversion rate from Type 3 transformation zone (TZ) to Types 1 or 2","The rate of participants with successful transformation from Type 3 (TZ) to Type 1 or 2 (TZ) will be calculated. It is the number of participants who successfully transformed from Type 3 TZ to Type 1 or 2 TZ, divided by the total number of participants in the entire randomized cohort.","Approximately 2-3 hours and approximately 4-6 hours since drug administration",[14],{"measure":15,"description":16,"timeFrame":17},"Comparison of the rate of patients converted from Type 3 TZ to Type 1 or 2 TZ between 2-3 hours and 4-6 hours","The rate of transformation from Type 3 transformation zone (TZ) to Type 1 or 2 TZ between 2-3 hours and 4-6 hours after administering misoprostol will be compared. The rate is calculated as the number of successful transformations within each time period (2-3 hours or 4-6 hours) divided by the total cohort.","Approximately 2-3 hours vs approximately 4-6 hours",null,{"allocation":20,"interventionModel":21,"interventionModelDescription":18,"primaryPurpose":22,"observationalModel":18,"timePerspective":18,"maskingInfo":23},"RANDOMIZED","SINGLE_GROUP","SCREENING",{"masking":24,"maskingDescription":25,"whoMasked":18},"NONE","The PIs, nurses who will be providing the drugs, and study participants will be blinded in the study.",[27],{"label":28,"type":29,"description":30,"interventionNames":31},"Non-pregnant women","EXPERIMENTAL","Non-pregnant women will either receive 600 mcg misoprostol (3 tablets) or identical placebo 3 (tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).",[32,33],"Drug: Placebo","Drug: Misoprostol",[35,40],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":18},"DRUG","Placebo","Participants will receive placebo (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).",[28],{"type":36,"name":41,"description":42,"armGroupLabels":43,"otherNames":18},"Misoprostol","Participants will receive 600 mcg misoprostol (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).",[28],[45],{"name":46,"affiliation":5,"role":47},"Warner K Huh, MD","PRINCIPAL_INVESTIGATOR",[49,53],{"name":46,"role":50,"phone":51,"phoneExt":18,"email":52},"CONTACT","2059341555","whuh@uabmc.edu",{"name":54,"role":50,"phone":55,"phoneExt":18,"email":56},"Simon M Manga, PhD","2059345612","smanga@uab.edu",[58],{"facility":59,"status":60,"city":61,"state":62,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"Cameroon Baptist Convention Health Core, EtougEbe Baptist Hospital Yaoundé","RECRUITING","Yaoundé","Center Region","2034","Cameroon","CM",{"type":67,"coordinates":68},"Point",[69,70],11.51667,3.86667,{"lat":70,"lon":69},[73,74,75,76],{"name":54,"role":50,"phone":55,"phoneExt":18,"email":56},{"name":46,"role":50,"phone":51,"phoneExt":18,"email":52},{"name":46,"role":47,"phone":18,"phoneExt":18,"email":18},{"name":54,"role":47,"phone":18,"phoneExt":18,"email":18},{"type":47,"investigatorFullName":78,"investigatorTitle":79,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Warner Huh","Professor",[81],{"name":82,"class":6},"Cameroon Baptist Convention Health","100567541","use-misoprostol-to-optimize-prevention-of-cervical-cancer-100567541",false,"NCT06669533","Use Misoprostol to Optimize Prevention of Cervical Cancer","Misoprostol to Optimizing Prevention of Cancer of the Cervix: A Double-Blind Randomized Controlled Trial","MISOPCx","Inclusion Criteria:\n\n* Diagnosis of Type 3 TZ confirmed on exam prior to randomization\n* Age 25 years or older\n\nExclusion Criteria:\n\n* With Type 1 or 2 TZ prior to randomization\n* Currently pregnant\n* History of hysterectomy\n* Any cancerous lesions\n* Active cervicitis",true,"FEMALE","25 Years",{"count":95,"type":96},420,"ESTIMATED","INTERVENTIONAL",[99],"NA","This is a double-blind randomized controlled trial of 420 non-pregnant women undergoing cancer screening by visual inspection with acetic acid (VIA) who have Type 3 transformation zone (TZ) and randomized to receive either Misoprostol or placebo.",[102],"Cervical Cancers",[104],"cervical cancers","2025-09-29",{"date":107,"type":108},"2025-10-01","ACTUAL",{"date":110,"type":108},"2025-02-25",{"date":112,"type":96},"2027-11-04",{"name":5,"class":6},1]